In the news release, The9 Signed a Definitive Share Purchase Agreement to Invest in GenAI LLM Digital Precision Medicine Platform for Brain Disease WM Therapeutic, issued 26-Mar-2024 by The9 Limited.
A recent study co-authored by Dr. Matthew Segar, a third-year cardiovascular disease fellow at The Texas Heart Institute and led by his research and residency mentor, University of Texas Southwestern Medical Center's Dr. Ambarish Pandey, utilized a machine learning-based approach to identify, understand, and predict diuretic responsiveness in patients with acute decompensated heart failure (ADHF).
Anavex Life Sciences Announces U S Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Real-world evidence (RWE) leader, Target RWE, today announced its innovative Precision Medicine Platform, a robust biorepository of 150,000+.